Summary
KL PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €384,626 and a net result of €50,690. Equity is growing by ~9.5% per year across the filed fiscal years. Its solvency ranks better than 56% of 6042 sector peers (fiscal year 2025). The company has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
-
99%
According to the 2025 annual accounts of KL PHARMA and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No directors read yet: 0 of 2 Gazette acts processed.